A Phase I study to determine the safety and immunogenicity of a new vaccine against the Middle East Respiratory Syndrome Coronavirus in Adults aged 50 to 70 years
Latest Information Update: 02 Feb 2024
At a glance
- Drugs Middle East respiratory syndrome coronavirus vaccine - Vaccitech (Primary)
- Indications Middle East respiratory syndrome coronavirus
- Focus Adverse reactions
Most Recent Events
- 15 Sep 2023 Planned End Date changed from 30 Sep 2024 to 31 Jan 2025.
- 27 Apr 2023 New trial record